Chronoscale Holdings Corp annual report, FY2019

Ekso Bionics Holdings, Inc. — FY 2019 Form 10-K

Reporting period: Fiscal year ended December 31, 2019; filed February 27, 2020. The filing identifies Ekso Bionics Holdings, Inc. as the registrant.

Business context

The company designs and sells wearable exoskeletons for medical rehabilitation and industrial applications. Its medical portfolio includes lower-limb rehabilitation devices EksoGT and the newer EksoNR, plus the upper-extremity rehabilitation device EksoUE. Industrial products include EksoVest and EksoZeroG. The company reported 68 employees at year-end.

Financial performance and position

MetricFY 2019FY 2018
Revenue$13.917 million$11.332 million
Gross profit / margin$6.764 million / 49%$4.309 million / 38%
Operating expenses$23.403 million$31.339 million
Operating loss$(16.639) million$(27.030) million
Net loss$(12.132) million$(26.992) million
Net loss per share, basic and diluted$(0.17)$(0.44)
Cash used in operating activities$(15.772) million$(22.165) million
Cash at year-end$10.872 million$7.655 million

Revenue increased 23%, mainly from higher EksoHealth sales, including conversions of rentals to purchases; EksoWorks revenue declined. EksoHealth revenue was $11.957 million, while EksoWorks generated $1.960 million. Gross margin improved chiefly through higher average selling prices and lower production costs for EksoGT and EksoNR. Operating expenses fell 25%, reflecting lower personnel, legal, clinical-trial, marketing and other costs.

The 2019 net loss included a $6.376 million non-cash gain from revaluing warrant liabilities, substantially influenced by the share-price decline; the improvement in net loss therefore does not represent operating profitability. The company reported $16.639 million of operating losses and $15.772 million of operating cash outflow.

At December 31, 2019, total assets were $21.915 million, total liabilities $15.118 million, and stockholders’ equity $6.797 million. Working capital was $11.0 million. Net note payable was $2.740 million; the loan matures January 2021 and carries a floating rate of 30-day U.S. LIBOR plus 5.41%. The loan requires minimum unrestricted cash equal to three months of cash burn; $3.564 million was subject to that requirement at year-end. Contractual obligations disclosed in the MD&A totaled $4.887 million, including debt, leases and purchase obligations.

Financing provided $19.039 million of net cash in 2019, including equity and warrant offerings, ATM sales and the China JV-related share purchase, partly offset by debt repayments. Shares outstanding rose from 62.963 million at year-end 2018 to 86.920 million at year-end 2019. The filing also disclosed 17.670 million outstanding warrants at year-end.

Material changes, outlook and risks

  • The company launched EksoUE and introduced EksoNR, which succeeds EksoGT. It booked 98 EksoGT and EksoNR units in 2019, including 17 rental units and 25 rental-to-sale conversions.
  • Management’s 2020 priorities include expanding rehabilitation adoption, launching EksoUE more broadly, developing industrial partnerships, extending selected Asian-market reach and lowering costs through the China JV. No numerical revenue or earnings guidance is provided.
  • The auditor issued an unqualified opinion on the financial statements and internal controls, but included a going-concern paragraph. Management said year-end cash was not forecast to fund operations for the following 12 months; it expected resources to support debt-covenant compliance only through the end of the third quarter of 2020 and said substantial additional financing was required. Management planned to seek financing and could reduce spending or curtail operations if it was unavailable.
  • CFIUS determined it had jurisdiction over the China JV review and imposed interim measures suspending company contributions and integration activities. The company expected review to conclude by April 13, 2020; the outcome and any mitigation requirements were unresolved in the filing. COVID-19 was identified as a potential risk to operations and supply chains.
  • The company reported a Nasdaq minimum-bid-price deficiency, with a March 16, 2020 deadline to regain compliance. Its February 21, 2020 closing share price was $0.38. Failure to comply could result in delisting.
  • Other material risks include continuing losses and cash burn, dependence on external financing and potential dilution, long hospital sales cycles, uncertain clinical evidence and adoption, regulatory and reimbursement uncertainty, competition, supplier dependence, and warrant terms that can create further dilution or cash obligations. The WISE clinical-study data was still being analyzed.
  • There were no material legal proceedings reported as ongoing in the supplied filing text; disclosed shareholder derivative actions were dismissed without settlement. The filing reported effective disclosure controls and internal control over financial reporting at year-end.

Important facts for investors to verify

  • Subsequent financing, cash burn, debt-covenant compliance and the company’s ability to fund operations beyond the third quarter of 2020.
  • Nasdaq bid-price compliance and any resulting reverse split or listing action.
  • CFIUS’s final determination, permitted technology transfers, and whether the China JV partners make required capital contributions.
  • Quarterly sales, margins, rental conversions, and whether EksoWorks demand and EksoUE commercialization develop as planned.
  • Warrant liabilities, exercise and repricing provisions, potential share dilution, and the company’s resulting fully diluted share count.
  • Clinical-study findings, regulatory clearances, payer support, and evidence of sustained customer adoption.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.